GILEAD SCIENCES, INC. Excess Tax Benefit from Share-based Compensation, Financing Activities
GILEAD SCIENCES, INC. (GILD) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $194.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2017-02-27
- GILEAD SCIENCES, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-12-31 was $32.00M, a 63.22% decline year-over-year.
- GILEAD SCIENCES, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-09-30 was $35.00M, a 79.65% decline year-over-year.
- GILEAD SCIENCES, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-06-30 was $38.00M, a 72.86% decline year-over-year.
- GILEAD SCIENCES, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-03-31 was $89.00M, a 52.15% decline year-over-year.
- GILEAD SCIENCES, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $194.00M, a 66.84% decline from fiscal 2015.
- GILEAD SCIENCES, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $585.00M, a 21.37% increase from fiscal 2014.
- GILEAD SCIENCES, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $482.00M, a 72.76% increase from fiscal 2013.
- GILEAD SCIENCES, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2013 was $279.00M, a 144.74% increase from fiscal 2012.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $32.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $67.00M derived: sum of 2 quarters · filed 2017-02-27 | $105.00M derived: sum of 3 quarters · filed 2017-02-27 | $194.00M 10-K · filed 2017-02-27 | ||||
| 2016-09-30 | $35.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $73.00M derived: sum of 2 quarters · filed 2016-11-07 | $162.00M 10-Q · filed 2016-11-07 | $249.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2016-06-30 | $38.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $127.00M 10-Q · filed 2016-08-05 | $214.00M derived: sum of 3 quarters · filed 2017-02-27 | $386.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2016-03-31 | $89.00M 10-Q · filed 2016-05-06 | $176.00M derived: sum of 2 quarters · filed 2017-02-27 | $348.00M derived: sum of 3 quarters · filed 2017-02-27 | $488.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-12-31 | $87.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $259.00M derived: sum of 2 quarters · filed 2017-02-27 | $399.00M derived: sum of 3 quarters · filed 2017-02-27 | $585.00M 10-K · filed 2017-02-27 | ||||
| 2015-09-30 | $172.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $312.00M derived: sum of 2 quarters · filed 2016-11-07 | $498.00M 10-Q · filed 2016-11-07 | $622.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-06-30 | $140.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $326.00M 10-Q · filed 2016-08-05 | $450.00M derived: sum of 3 quarters · filed 2017-02-27 | $594.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-03-31 | $186.00M 10-Q · filed 2016-05-06 | $310.00M derived: sum of 2 quarters · filed 2017-02-27 | $454.00M derived: sum of 3 quarters · filed 2017-02-27 | $511.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2014-12-31 | $124.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $268.00M derived: sum of 2 quarters · filed 2017-02-27 | $325.00M derived: sum of 3 quarters · filed 2017-02-27 | $482.00M 10-K · filed 2017-02-27 | ||||
| 2014-09-30 | $144.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $201.00M derived: sum of 2 quarters · filed 2015-11-04 | $358.00M 10-Q · filed 2015-11-04 | $357.93M 10-Q · filed 2014-11-05 | $468.27M derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2014-06-30 | $57.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $214.00M 10-Q · filed 2015-08-05 | $214.26M 10-Q · filed 2014-08-04 | $324.27M derived: sum of 3 quarters · filed 2016-02-24 | $403.85M derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2014-03-31 | $157.00M 10-Q · filed 2015-05-08 | $156.69M 10-Q · filed 2014-05-07 | $267.27M derived: sum of 2 quarters · filed 2016-02-24 | $346.85M derived: sum of 3 quarters · filed 2016-02-24 | $395.25M derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2013-12-31 | $110.27M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $189.85M derived: sum of 2 quarters · filed 2016-02-24 | $238.25M derived: sum of 3 quarters · filed 2016-02-24 | $279.00M 10-K · filed 2016-02-24 | $278.77M 10-K · filed 2014-02-25 | |||
| 2013-09-30 | $79.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $127.98M derived: sum of 2 quarters · filed 2014-11-05 | $168.73M 10-Q · filed 2014-11-05 | $217.77M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-06-30 | $48.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $89.15M 10-Q · filed 2014-08-04 | $138.20M derived: sum of 3 quarters · filed 2015-02-25 | $167.71M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-03-31 | $40.75M 10-Q · filed 2014-05-07 | $89.79M derived: sum of 2 quarters · filed 2015-02-25 | $119.31M derived: sum of 3 quarters · filed 2015-02-25 | $131.44M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2012-12-31 | $49.05M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $78.56M derived: sum of 2 quarters · filed 2015-02-25 | $90.70M derived: sum of 3 quarters · filed 2015-02-25 | $114.00M 10-K · filed 2015-02-25 | $114.24M 10-K · filed 2013-02-27 | |||
| 2012-09-30 | $29.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31 | $41.65M derived: sum of 2 quarters · filed 2013-10-31 | $64.95M 10-Q · filed 2013-10-31 | $75.55M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $12.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $35.44M 10-Q · filed 2013-08-01 | $46.03M derived: sum of 3 quarters · filed 2014-02-25 | $55.99M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $23.30M 10-Q · filed 2013-05-08 | $33.90M derived: sum of 2 quarters · filed 2014-02-25 | $43.85M derived: sum of 3 quarters · filed 2014-02-25 | $49.90M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $10.59M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $20.55M derived: sum of 2 quarters · filed 2014-02-25 | $26.59M derived: sum of 3 quarters · filed 2014-02-25 | $40.85M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $9.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $16.00M derived: sum of 2 quarters · filed 2012-11-06 | $30.25M 10-Q · filed 2012-11-06 | $43.23M derived: sum of 4 quarters · filed 2013-02-27 | ||||
| 2011-06-30 | $6.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | $20.30M 10-Q · filed 2012-08-01 | $33.28M derived: sum of 3 quarters · filed 2013-02-27 | $41.23M derived: sum of 4 quarters · filed 2013-02-27 | ||||
| 2011-03-31 | $14.26M 10-Q · filed 2012-05-04 | $27.23M derived: sum of 2 quarters · filed 2013-02-27 | $35.19M derived: sum of 3 quarters · filed 2013-02-27 | $46.06M derived: sum of 4 quarters · filed 2013-02-27 | ||||
| 2010-12-31 | $12.98M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $20.93M derived: sum of 2 quarters · filed 2013-02-27 | $31.80M derived: sum of 3 quarters · filed 2013-02-27 | $81.62M 10-K · filed 2013-02-27 | ||||
| 2010-09-30 | $7.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $18.82M derived: sum of 2 quarters · filed 2011-11-04 | $68.64M 10-Q · filed 2011-11-04 | $89.56M derived: sum of 4 quarters · filed 2012-02-23 | ||||
| 2010-06-30 | $10.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | $60.69M 10-Q · filed 2011-08-05 | $81.61M derived: sum of 3 quarters · filed 2012-02-23 | $107.19M derived: sum of 4 quarters · filed 2012-02-23 | ||||
| 2010-03-31 | $49.82M 10-Q · filed 2011-05-09 | $70.74M derived: sum of 2 quarters · filed 2012-02-23 | $96.32M derived: sum of 3 quarters · filed 2012-02-23 | $109.31M derived: sum of 4 quarters · filed 2012-02-23 | ||||
| 2009-12-31 | $20.92M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $46.50M derived: sum of 2 quarters · filed 2012-02-23 | $59.49M derived: sum of 3 quarters · filed 2012-02-23 | $80.19M 10-K · filed 2012-02-23 | ||||
| 2009-09-30 | $25.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $38.58M derived: sum of 2 quarters · filed 2010-11-08 | $59.27M 10-Q · filed 2010-11-08 | $95.48M derived: sum of 4 quarters · filed 2011-02-28 | ||||
| 2009-06-30 | $12.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-09 | $33.68M 10-Q · filed 2010-08-09 | $69.90M derived: sum of 3 quarters · filed 2011-02-28 | $105.03M derived: sum of 4 quarters · filed 2011-02-28 | ||||
| 2009-03-31 | $20.69M 10-Q · filed 2010-05-10 | $56.91M derived: sum of 2 quarters · filed 2011-02-28 | $92.04M derived: sum of 3 quarters · filed 2011-02-28 | |||||
| 2008-12-31 | $36.22M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $71.34M derived: sum of 2 quarters · filed 2011-02-28 | $191.94M 10-K · filed 2011-02-28 | |||||
| 2008-09-30 | $35.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-05 | $155.72M 10-Q · filed 2009-11-05 | ||||||
| 2008-06-30 | $120.59M 10-Q · filed 2009-08-05 | |||||||
| 2007-12-31 | $76.28M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |